Latest news with #HelenFang
Yahoo
30-05-2025
- Business
- Yahoo
Acclaro Medical secures $23m in Series B funding for skin laser technologies
Acclaro Medical has completed a Series B funding round, raising $23m, to spur the growth of its flagship products, UltraClear and AuraLux, and facilitate the company's global market expansion. Accelmed Partners spearheaded the funding round, which also received support from the current investor, 3E Bioventures Capital. Acclaro Medical co-founder and CEO Helen Fang said: "This funding empowers us to continue our strong growth and realise our vision of improving the quality of life for people of all skin colours and all ages worldwide." UltraClear comprises a 2,910nm cold ablative fibre laser that leverages 3DIntelliPulse technology and offers enhanced safety across all types of skin. Cleared by the US Food and Drug Administration (FDA), UltraClear operates by vaporising the skin's damaged outer layers and heating the underlying layers with controlled thermal energy, promoting the growth of new cells and boosting elastin and collagen production. According to Acclaro Medical, the laser's cold beams aid in the removal of damaged epidermal cells, reducing side effects and pain. Its beam quality facilitates consistent resurfacing outcomes, akin to an advanced form of exfoliation. Alongside UltraClear, the company's AuraLux laser utilises the exclusive Cool Pulse technology. This expansion of the product line aims to enhance accessibility for providers and their patients. Acclaro Medical co-founder and president Shlomo Assa said: "We are thrilled to have the support of Accelmed as we expand our global and domestic footprint. This Series B funding is a strong vote of confidence in our mission to bring UltraClear and AuraLux to more people pursuing anti-ageing solutions for healthier and younger-looking skin. 'It greatly enables us to accelerate product development, expand our team, and reach more customers globally." In 2022, Acclaro Corporation introduced the UltraClear laser technology system in the US. "Acclaro Medical secures $23m in Series B funding for skin laser technologies" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Cision Canada
29-05-2025
- Business
- Cision Canada
Acclaro Medical Raises $23 Million in Series B Funding Led by Accelmed Partners to Advance Groundbreaking 2910 nm Fiber Laser Technology
Accelmed $20 Million Investment with 3E Bioventures Capital Funding of $3 Million to Drive Innovation, Clinical Expansion, and Global Market Growth SMITHFIELD, R.I., May 29, 2025 /CNW/ -- Acclaro Medical, a pioneering medical technology company focused on developing cutting-edge solutions that improve patient care and redefine medical practices, proudly announces the successful completion of its Series B funding round. Led by Accelmed Partners with participation by existing investor 3E Bioventures Capital, the combined funding of $23 million marks a pivotal milestone in the company's journey to fulfill unmet aesthetic needs through its innovative 2910 nm fiber laser solution and other disruptive technologies. This capital infusion will help Acclaro accelerate the growth of its flagship products, UltraClear ® and AuraLux ™ and expedite global market expansion while advancing development of new trailblazing products in its pipeline. Acclaro Medical's UltraClear fiber laser is recognized by leading aesthetic professionals as a breakthrough in Total Skin Health that treats multiple skin layers to help reverse the signs of aging and gravity. The first of its kind 2910 nm cold ablative fiber laser, powered by proprietary 3DIntelliPulse ™ technology, delivers: "The funding is a testament to our unstoppable team and tremendous progress Acclaro has made in a very short duration." Post this Unparalleled clinical efficacy Superior patient experiences Unmatched versatility Significantly improved safety for all skin types, including previously high-risk skin-of-color patients. Its precision-engineered capabilities make it the ideal choice for practitioners seeking transformative results with minimal downtime, reduced patient discomfort and speedy healing. Complementing UltraClear, the AuraLux laser leverages the same exclusive Cool Pulse ™ technology and broadens accessibility for aesthetic providers and their patients while maintaining Acclaro's hallmark quality. "Securing this Series B investment is a powerful testament to our unstoppable team and the tremendous progress that Acclaro has made in a very short period of time," said Acclaro Medical CEO and Co-founder Helen Fang. "This funding empowers us to continue our strong growth and realize our vision of improving the quality of life for people of all skin colors and all ages worldwide." Shlomo Assa, President and co-founder of Acclaro Medical, noted: "We are thrilled to have the support of Accelmed as we expand our global and domestic footprint. This Series B funding is a strong vote of confidence in our mission to bring UltraClear and AuraLux to more people pursuing anti-aging solutions for healthier and younger-looking skin. It greatly enables us to accelerate product development, expand our team, and reach more customers globally – And we're just getting started!" The Series B funding will allow Acclaro Medical to leverage decades of Accelmed's operational and financial expertise, alongside 3E Bioventures' disciplined efficiency. Acclaro Medical is poised to execute its strategic plans and realize its vision of revolutionizing the aesthetic industry. These efforts will further cement the company's position as a leader in providing innovative, patient-centered skin health solutions. "Acclaro's unique cold laser fiber technology constitutes a game changer in laser aesthetics with the possibility for aesthetic practices to safely treat all skin types for all major indications using only one device," stated Daniel Cohen, Accelmed's venture partner with extensive experience leading successful Medtech & Biotech investments over the last 20 years. "Accelmed Partners is thrilled to lead this round of financing and accompany Acclaro' s management in this fantastic journey." About Acclaro Medical Founded in 2018 by world-class industry experts, Acclaro Medical is committed to developing, innovating and bringing to market game-changing solutions to address today's unmet medical, aesthetic and surgical practice needs. With a relentless commitment to innovation and a team of dedicated professionals, Acclaro Medical continues to push the boundaries and drive positive change in the aesthetic medical industry. Its proprietary 3DMIRACL ™ and Laser Coring ™ skin rejuvenation treatments are valued for offering unrivaled aesthetic results complemented by high patient comfort, rapid healing and utmost safety across all skin types. For more information, please visit About Accelmed Partners Accelmed, a leader in healthcare technology investing, is renowned for its private equity approach to a sector traditionally dominated by venture and early-stage growth firms. Its team of experienced industry veterans and company builders work closely as a trusted partner with portfolio management to improve operations, upgrade product portfolios, and strengthen commercial organizations. Accelmed's support and resources are designed to help portfolio companies like Acclaro Medical elevate its technology and achieve enduring success. The investment firm currently manages over $630 million of equity capital. For more information, please visit
